Podcast appearances and mentions of James B Adams

This week, we are joined by Dr. James B. Adams, a President's Professor at Arizona State University and leader of the Autism/Asperger's Research Group. As a father to an adult daughter with autism, Dr. Adams has dedicated much of his research to uncovering biological causes and innovative treatments for autism. Today, we'll explore groundbreaking work on the gut-brain connection, including a new diagnostic urine test and Microbiota Transplant Therapy (MTT), which has shown promise in improving gut health and autism symptoms. Download latest episode to learn more! Resources GBAT Facebook: https://www.facebook.com/gutbrainaxisinfo  Instagram: @gutbrainaxisinfo ANRC Facebook: https://www.facebook.com/autismnutrition/ Instagram: @autismnrc  ............................................................... Autism weekly is now found on all of the major listening apps including apple podcasts, google podcasts, stitcher, Spotify, amazon music, and more. Subscribe to be notified when we post a new podcast. Autism weekly is produced by ABS Kids. ABS Kids is proud to provide diagnostic assessments and ABA therapy to children with developmental delays like Autism Spectrum Disorder. You can learn more about ABS Kids and the Autism Weekly podcast by visiting abskids.com.

I this episode we speak with Dr. James Adams about this research in the area of autism and possible links to the microbiome. James B. Adams, Ph.D., is the Director of the Autism/Asperger's Research Program at Arizona State University. His research focuses on the medical causes of autism and how to treat and prevent it including the areas of nutrition (vitamins/minerals, essential fatty acids, carnitine, digestive enzymes, special diets), oxidative stress, gut problems, gut bacteria, toxic metals, and seizures. He has published over 150 peer-reviewed scientific articles, including over 40 related to autism. He is also the President of the Autism Society of Greater Phoenix, the President of the Autism Nutrition Research Center, the co-leader of the Scientific Advisory Committee of the Autism Research Institute, and chair of the Scientific Advisory Board of the Neurological Health Foundation. He has an adult daughter with autism. Learning Points: 1. What are key prenatal nutrients that moms need to be aware of to minimize the risk of having a child with autism? 2. What is Microbiota transplant? 3. How is this improving the health of children with autism? Website Addresses www.adamsautismresearch.com www.autismNRC.org

This episode is also available as a blog post: https://fierceautie.com/2020/01/18/quack-exposed-james-b-adams/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Roberta Jenero, welcomes James B. Adams, Ph.D. President’s Professor at Arizona State University and the President of The Autism Nutrition Research Center discusses nutrition research breakthroughs in prenatal prevention of autism and proper diet and supplementation in the management of autism. Be sure to like us on Facebook!

 Autism & Fecal Microbiota Transfer Therapy - MTT - FMT - UpdateJames B. Adams, Ph.D., is a President's Professor at Arizona State University, where he directs the autism/Asperger's research program, though he originally taught chemical and materials engineering there. Dr. Adams also holds a post at the Southwest College of Naturopathic Medicine. He is also the president of the Autism Society of Greater Phoenix, the co-chair of the Autism Research Institute's scientific advisory committee, and has received the Autism Service Award from the Greater Phoenix chapter of the Autism Society of America. In this episode, he reports on microbiota transfer therapy. This CBJ/301 is a republication of CBJ/214 and is selected because it reveals a most interesting development in Autism Treatment directly related to gut microbiota and his research with FMTT Fecal Microbiota Transfer Therapy. Must listen! Photo by https://unsplash.com/photos/4zgiTS_qT1k?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText (Artak Petrosyan) on https://unsplash.com/search/photos/maps?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText (Unsplash) Reference Details For MTT: Article AbstractMicrobiota Transfer Therapy alters the gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Publication Microbiome - Jan. 23, 2017 Author(s) Dae-Wook Kang, James B. Adams, Ann C. Gregory, Thomas Borody, Lauren Chittick5,15, Alessio Fasano, Alexander Khoruts, Elizabeth Geis, Juan Maldonado, Sharon McDonough-Means, Elena L. Pollard, Simon Roux, Michael J. Sadowsky, Karen Schwarzberg Lipson, Matthew B. Sullivan, J. Gregory Caporaso and Rosa Krajmalnik-Brown BackgroundAutism spectrum disorders (ASD) are complex neurobiological disorders that impair social interactions and communication and lead to restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. The causes of these disorders remain poorly understood, but gut microbiota, the 1013 bacteria in the human intestines, have been implicated because children with ASD often suffer gastrointestinal (GI) problems that correlate with ASD severity. Several previous studies have reported abnormal gut bacteria in children with ASD. The gut microbiome-ASD connection has been tested in a mouse model of ASD, where the microbiome was mechanistically linked to abnormal metabolites and behavior. Similarly, a study of children with ASD found that oral non-absorbable antibiotic treatment improved GI and ASD symptoms, albeit temporarily. Here, a small open-label clinical trial evaluated the impact of Microbiota Transfer Therapy (MTT) on gut microbiota composition and GI and ASD symptoms of 18 ASD-diagnosed children. ResultsMTT involved a 2-week antibiotic treatment, a bowel cleanse, and then an extended fecal microbiota transplant (FMT) using a high initial dose followed by daily and lower maintenance doses for 7–8 weeks. The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain. ConclusionsThis exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and virome and improve GI and behavioral symptoms of ASD. Improvements in GI symptoms, ASD symptoms, and the microbiome all persisted for at least 8 weeks after treatment ended, suggesting a long-term impact. Similarly, clinical assessments showed that behavioral ASD symptoms improved significantly and remained improved 8 weeks after treatment ended. Bacterial and phagedeep sequencing analyses revealed successful partial engraftment of donor microbiota and beneficial changes in the gut environment. Specifically, overall bacterial diversity and the abundance of Bifidobacterium, Prevotella, and Desulfovibrio among other taxa...

 Autism & Fecal Microbiota Transfer Therapy - MTT - FMT - UpdateJames B. Adams, Ph.D., is a President's Professor at Arizona State University, where he directs the autism/Asperger's research program, though he originally taught chemical and materials engineering there. Dr. Adams also holds a post at the Southwest College of Naturopathic Medicine. He is also the president of the Autism Society of Greater Phoenix, the co-chair of the Autism Research Institute's scientific advisory committee, and has received the Autism Service Award from the Greater Phoenix chapter of the Autism Society of America. This CBJ/214 reveals a most interesting development in Autism Treatment directly related to gut microbiota and his research with FMTT Fecal Microbiota Transfer Therapy. Must listen! Photo by https://unsplash.com/photos/4zgiTS_qT1k?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText (Artak Petrosyan) on https://unsplash.com/search/photos/maps?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText (Unsplash) Reference Details For MTT: Article AbstractMicrobiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Publication Microbiome - Jan. 23, 2017 Author(s) Dae-Wook Kang, James B. Adams, Ann C. Gregory, Thomas Borody, Lauren Chittick5,15, Alessio Fasano, Alexander Khoruts, Elizabeth Geis, Juan Maldonado, Sharon McDonough-Means, Elena L. Pollard, Simon Roux, Michael J. Sadowsky, Karen Schwarzberg Lipson, Matthew B. Sullivan, J. Gregory Caporaso and Rosa Krajmalnik-Brown BackgroundAutism spectrum disorders (ASD) are complex neurobiological disorders that impair social interactions and communication and lead to restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. The causes of these disorders remain poorly understood, but gut microbiota, the 1013 bacteria in the human intestines, have been implicated because children with ASD often suffer gastrointestinal (GI) problems that correlate with ASD severity. Several previous studies have reported abnormal gut bacteria in children with ASD. The gut microbiome-ASD connection has been tested in a mouse model of ASD, where the microbiome was mechanistically linked to abnormal metabolites and behavior. Similarly, a study of children with ASD found that oral non-absorbable antibiotic treatment improved GI and ASD symptoms, albeit temporarily. Here, a small open-label clinical trial evaluated the impact of Microbiota Transfer Therapy (MTT) on gut microbiota composition and GI and ASD symptoms of 18 ASD-diagnosed children. ResultsMTT involved a 2-week antibiotic treatment, a bowel cleanse, and then an extended fecal microbiota transplant (FMT) using a high initial dose followed by daily and lower maintenance doses for 7–8 weeks. The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain. ConclusionsThis exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and virome and improve GI and behavioral symptoms of ASD. Improvements in GI symptoms, ASD symptoms, and the microbiome all persisted for at least 8 weeks after treatment ended, suggesting a long-term impact. Similarly, clinical assessments showed that behavioral ASD symptoms improved significantly and remained improved 8 weeks after treatment ended. Bacterial and phagedeep sequencing analyses revealed successful partial engraftment of donor microbiota and beneficial changes in the gut environment. Specifically, overall bacterial diversity and the abundance of Bifidobacterium, Prevotella, and Desulfovibrio among other taxa increased following MTT, and these changes persisted after treatment stopped (followed for 8 weeks)....

Learn the Unique Metabolic and Nutritional Requirements in Autism and How To Approach These Complexed Patients Kirk Hamilton interviews Dr. James B. Adams who earned his Ph.D. in Materials Science & Engineering from University of Wisconsin-Madison in 1987. Currently Dr. Adams is a professor at Arizona State University doing research in developing computational models of materials and applying those models to the study of properties of materials. He is conducting research on heavy metal toxicity and autism and recently co-authored paper entitled "Nutritional and Metabolic Status of Children with Autism vs. Neurotypical Children, and the Association with Autism Severity" in Nutrition and Metabism in 2011. He is also the parent of an autistic child, director of the Arizona State University Autism/Asperger's Research Program and the President of the Greater Phoenix Chapter of the Autism Society of America. Download or Open: